ReviewFrontiers in oncology2019
The Emerging Roles of Heparan Sulfate 3-
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Identification of drug responsible glycogene signature in liver carcinoma from meta-analysis using RNA-seq data.Glycoconjugate journal · 2024Pooled it
- A study on the correlation between DNA methylation and protein expression levels ofThe Journal of international medical research · 2026Article
- RNA-binding protein PTBP1 mediates HSV-1 attachment and infection through regulation of heparan sulfate 3-O-sulfotransferase gene expression.Cell & bioscience · 2025Article
- Dynamic allelic expression in mouse mammary glands across the adult developmental cycle.Nucleic acids research · 2025Article
- Genomic analyses identify 15 risk loci and revealProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Identification and characterization of mitochondrial autophagy-related genes in osteosarcoma and predicting clinical prognosis.Scientific reports · 2025Article
- Heparan sulfate chains in hepatocellular carcinoma.Gastroenterology report · 2025Review
- Elucidation of toxic effects of 1,2-diacetylbenzene: an in silico study.Forensic toxicology · 2025Article
- Epigenetic Targeting of Heparan Sulfate 3-ACS pharmacology & translational science · 2024Article
- MEG3-Mediated Oral Squamous-Cell-Carcinoma-Derived Exosomal miR-421 Activates Angiogenesis by Targeting HS2ST1 in Vascular Endothelial Cells.International journal of molecular sciences · 2024Article
- Stage Analysis of Breast Cancer Metabolomics: A System Biology Approach.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- A novel signature constructed by super-enhancer-related genes for the prediction of prognosis in hepatocellular carcinoma and associated with immune infiltration.Frontiers in oncology · 2023Article
- Alterations in heparan sulfate proteoglycan synthesis and sulfation and the impact on vascular endothelial function.Matrix biology plus · 2022Review
- Importance of Heparan Sulfate Proteoglycans in Pancreatic Islets and β-Cells.International journal of molecular sciences · 2022Review
- Heparan Sulfate and Sialic Acid in Viral Attachment: Two Sides of the Same Coin?International journal of molecular sciences · 2022Review
- Molecular dynamics-based descriptors of 3-O-Sulfated Heparan sulfate as contributors of protein binding specificity.Computational biology and chemistry · 2022Article
- Review
- ordinalbayes: Fitting Ordinal Bayesian Regression Models to High-Dimensional Data Using R.Stats · 2022Article
- Integrated Deadenylase Genetic Association Network and Transcriptome Analysis in Thoracic Carcinomas.Molecules (Basel, Switzerland) · 2022Article
- Spatiotemporal diversity and regulation of glycosaminoglycans in cell homeostasis and human disease.American journal of physiology. Cell physiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alteration in the expression of heparan sulfate (HS)-modifying enzymes has been frequently observed in cancer. Consequently, dysregulation of the HS biosynthetic machinery results in dramatic changes in the HS structure, thereby impacting a range of pivotal cellular processes involved in tumorigenesis and cancer progression including proliferation, migration, apoptosis, and immune escape. HS 3-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.